Essential Thrombocythemia Clinical Trial


Study Information

Study Title

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST)

Study Summary

The purpose of this prospective, longitudinal, non-interventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).

Principal Investigator

Myron Bednar, MD

Phase IV

If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.

This Study is now Closed

Contact HHO

All questions and feedback are welcome, anytime.






    About HHO


    Hunterdon Hematology Oncology is a community oncology group, dedicated to fighting cancer in this community and across the region. Our Doctors, Physician’s Assistants and Nurses work tirelessly. They fight hard so that you can win.




    Subscribe


    Sign up for the HHO newsletter to stay up to date on the latest news within the practice and the community.



      © HHO 2022. All rights reserved. Designed by DRAW